Universität zu Köln

Wagner, Britta Janina and Buettner, Reinhard (2020). Immunohistochemical and molecular pathological diagnosis of lung carcinoma. Pathologe, 41 (1). S. 3 - 14. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Full text not available from this repository.

Abstract

The therapy of lung cancer has revolutionarily changed within the last 15 years. The prognosis of patients has dramatically improved due to targeted therapies, for instance tyrosine kinase inhibitors (TKI). Current recruiting studies are testing new MET-, KRAS-, ROS1-, RET- and NTRK-inhibitors. The first clinical data are promising, emphasizing that it remains a future challenge for pathologists and oncologists to keep an eye on all facets of therapy options. Today, precise lung cancer classification via immunohistochemistry and molecular pathology is crucial for the therapy and prognosis of patients. Further, new biopsy technologies lead to very small tumor tissue samples and cytological samples of high diagnostic quality. Therefore, the complexity of diagnosis needs a strategic procedure to minimize loss of tissue material. This assay gives an overview of efficient and target-orientated diagnostic procedures in consideration of current clinical trials.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wagner, Britta Janina UNSPECIFIED UNSPECIFIED UNSPECIFIED Buettner, Reinhard UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-348940
DOI:	10.1007/s00292-019-00732-4
Journal or Publication Title:	Pathologe
Volume:	41
Number:	1
Page Range:	S. 3 - 14
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1963
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language LIQUID BIOPSY; CANCER; MET; NIVOLUMAB; PATIENT Multiple languages Pathology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/34894